Commercial Credit Report for Oxford Cannabinoid Tchnlgs Hldngs PLC

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Oxford Cannabinoid Tchnlgs Hldngs PLC is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Oxford Cannabinoid Tchnlgs Hldngs PLC
Prama House, 267 Banbury Road
Phone: +44 2030342820p:+44 2030342820	OXFORD, OX2 7HT United Kingdom

This company is no longer actively traded on any major stock exchange.

Business Summary

Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
10/31/2023	4/30/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2833	Medicinal chemicals and botanical products
8731	Commercial physical and biological research

Business Names

Business Name
OCT Hellas Pharmaceuticals Research & Development Laboratory S.A.
Oxford Cannabinoid Technologies Ltd

General Information

Number of Employees:	7	(As of 4/30/2023)
Outstanding Shares:	1,088,415,644	(As of 2/20/2024)
Stock Exchange:	LON

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN